Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

Abstract Background/objective REFLECTIONS B538–02 is a randomized, double-blind comparative study of the adalimumab (ADL) biosimilar PF-06410293, (ADL-PF), and reference ADL sourced from the European Union (ADL-EU) in patients with active RA. Therapeutic equivalence was demonstrated based on ACR20 r...

Full description

Bibliographic Details
Main Authors: Roy M. Fleischmann, Daniel F. Alvarez, Amy E. Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke Alten
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Arthritis Research & Therapy
Subjects:
Adalimumab
Adalimumab-afzb
Biosimilar
PF-06410293
Rheumatoid arthritis
Long-term
Online Access:https://doi.org/10.1186/s13075-021-02626-4

Internet

https://doi.org/10.1186/s13075-021-02626-4

Similar Items